OCT 22, 2019 10:34 PM PDT

Using senolytics to treat cancer

New research published in Nature Metabolism proposes using an already existing drug – a cardiac glycoside called ouabain – as a senolytic to kill off damaged aging or cancerous cells. Senolytics are a class of drugs that are capable of selectively killing senescent cells, or cells that have reached their natural aging process. Although senescence is normal, previous studies have shown that senescent cells can contribute to the spread and growth of cancer tumors.

While past research has identified some senolytics with potential anti-cancer properties, those tested up until now have also had serious side effects. However, the researchers behind the new study believe that ouabain may offer a safer alternative broad-spectrum senolytic, capable of targeting a varied array of aging cells. The research team hails from the MRC London Institute of Medical Sciences in the United Kingdom.

Senior author Professor Jesús Gil commented on the potential of ouabain, saying "These drugs are already used in the clinic, so they could be repurposed to treat a long list of diseases, including cancer. This is something we are keen to explore with our clinical collaborators. Moreover, many patients are being treated with digoxin, and an epidemiologist could look retrospectively and ask the question of whether those patients who were treated with digoxin are doing better than those who weren't."

Digoxin is another type of cardiac glycoside and is in the same class of drugs as ouabain. These drugs are usually prescribed to treat cardiac arrhythmias and atrial fibrillation; however, when the researchers experimented with them to see how they affect healthy and senescent cells, they discovered that ouabain, in particular, is capable of selectively killing aging cells.

In the study, which was conducted in aging mice with precancerous lesions in the liver and after radiotherapy, the team found that ouabain was successful in killing cells senescent from cancer as well as those senescent from exposure to radiotherapy or chemotherapy.

The authors say that future studies should continue to consider the potential of cardiac glycosides as senolytics in cancer treatments. They hope to continue their investigations in this field.

Sources: Nature Metabolism, Medical News Today

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
APR 16, 2020
Cancer
APR 16, 2020
The Unseen Barriers Surrounding Pancreatic Cancer
Pancreatic cancer is one of the deadliest cancers in the world. With a poor five year prognosis and lack of effective tr ...
APR 16, 2020
Cancer
APR 16, 2020
This drug hopes to prevent cancer relapse
A report published in Nature Communications highlights findings from a study showing that the experimental drug, Qu ...
APR 27, 2020
Cancer
APR 27, 2020
The Tumor Suppressor and its Regulator: An Indirect Oncogene
Oncogenes, mutations in genes that promote cancer growth, have long been easy targets for cancer research due to the dir ...
MAY 04, 2020
Cancer
MAY 04, 2020
A Retroactive Study Finds an Immunotherapy Effective as a Third-Line Therapy
Cancer is a particularly persistent disease. Many therapies are composed of one or more different treatments. These trea ...
MAY 10, 2020
Genetics & Genomics
MAY 10, 2020
Towards a Targeted Elimination of Leukemic Cells
Our blood carries many types of critical cells, including platelets, red blood cells, and white blood cells, which are m ...
MAY 14, 2020
Clinical & Molecular DX
MAY 14, 2020
New Tech Has Its AI on Brain Tumors
  A collaboration across 29 research and healthcare agencies is putting together the world’s largest brain tu ...
Loading Comments...